The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) is a huge mover today! The stock increased 3.42% or $1.98 during the last trading session, hitting $59.94. About 73,986 shares traded hands. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has risen 20.15% since April 22, 2016 and is uptrending. It has outperformed by 14.74% the S&P500.
The move comes after 7 months positive chart setup for the $708.72 million company. It was reported on Nov, 25 by Barchart.com. We have $63.54 PT which if reached, will make NASDAQ:ANIP worth $42.52 million more.
Analysts await ANI Pharmaceuticals Inc (NASDAQ:ANIP) to report earnings on February, 28. They expect $1.02 EPS, up 137.21% or $0.59 from last year’s $0.43 per share. ANIP’s profit will be $12.06 million for 14.69 P/E if the $1.02 EPS becomes a reality. After $1.02 actual EPS reported by ANI Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Ratings Coverage
Out of 5 analysts covering ANI Pharma (NASDAQ:ANIP), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. ANI Pharma has been the topic of 13 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Roth Capital upgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) rating on Monday, September 28. Roth Capital has “Buy” rating and $60 price target. The company was maintained on Friday, August 5 by Oppenheimer. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Buy” rating given on Friday, November 13 by Standpoint Research. The firm earned “Strong Buy” rating on Thursday, June 23 by Raymond James. The stock has “Perform” rating given by Oppenheimer on Tuesday, July 19. As per Tuesday, May 24, the company rating was downgraded by Standpoint Research. On Tuesday, August 4 the stock rating was maintained by TH Capital with “Neutral”. TheStreet downgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) on Wednesday, September 2 to “Buy” rating. The company was upgraded on Monday, September 28 by TH Capital. As per Friday, July 31, the company rating was maintained by Oppenheimer.
According to Zacks Investment Research, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.”
Insitutional Activity: The institutional sentiment increased to 2.33 in Q2 2016. Its up 0.82, from 1.51 in 2016Q1. The ratio increased, as 14 funds sold all ANI Pharmaceuticals Inc shares owned while 31 reduced positions. 28 funds bought stakes while 40 increased positions. They now own 5.41 million shares or 2.90% less from 5.57 million shares in 2016Q1.
Blackrock Institutional Na has invested 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Winslow Evans & Crocker owns 8 shares or 0% of their US portfolio. Royal National Bank Of Canada owns 221 shares or 0% of their US portfolio. Us Bank De accumulated 116 shares or 0% of the stock. The Unknown-based Mckinley Mngmt Ltd Liability Delaware has invested 0.14% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Smith Asset Mngmt Grp Lp accumulated 59,720 shares or 0.1% of the stock. Nomura Holdings accumulated 181,064 shares or 0.03% of the stock. Texas Permanent School Fund last reported 0% of its portfolio in the stock. Thomson Horstmann & Bryant Inc last reported 0.07% of its portfolio in the stock. Thrivent Fincl For Lutherans, a Minnesota-based fund reported 3,660 shares. State Bank Of Montreal Can last reported 3,177 shares in the company. Diker Management Lc last reported 10,900 shares in the company. Aqr Limited Com accumulated 12,126 shares or 0% of the stock. Ativo Capital Ltd Company last reported 0.23% of its portfolio in the stock. The Quebec – Canada-based Pub Sector Pension Board has invested 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Insider Transactions: Since August 8, 2016, the stock had 0 insider buys, and 2 selling transactions for $3.35 million net activity. On Monday, August 22 PRZYBYL ARTHUR sold $2.51 million worth of the stock or 37,455 shares. $838,209 worth of shares were sold by Schrepfer Robert W on Monday, August 8.
More notable recent ANI Pharmaceuticals Inc (NASDAQ:ANIP) news were published by: Prnewswire.com which released: “ANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide …” on July 18, 2016, also Prnewswire.com with their article: “ANI Pharmaceuticals Announces Launch of Erythromycin Ethylsuccinate for Oral …” published on September 27, 2016, Prnewswire.com published: “ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and …” on October 27, 2016. More interesting news about ANI Pharmaceuticals Inc (NASDAQ:ANIP) were released by: Prnewswire.com and their article: “ANI Pharmaceuticals Announces Launch of Hydroxyprogesterone Caproate Injection …” published on June 28, 2016 as well as Prnewswire.com‘s news article titled: “ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full …” with publication date: August 04, 2016.
ANIP Company Profile
ANI Pharmaceuticals, Inc. (ANI), incorporated on April 11, 2001, is an integrated specialty pharmaceutical company. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. The Firm has approximately two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. The Company’s two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet. The facilities are specialized with various capabilities, enabling the Company to manufacture liquid, powder, and oral solid-dose products, topicals, controlled substances and products. It also performs contract manufacturing for other pharmaceutical companies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.